What did @rachelepojednic actually say?
Dr. Rachel Pojednic's core argument is that "a peptide being naturally occurring doesn't make it a natural therapy." She's drawing a line between what your body produces and what happens when you inject, inhale, or apply a synthetic version of that same molecule. She also flags that many peptides circulating online exist in a regulatory gray zone, sold under "research purposes" labeling as legal cover, and that this makes scientific evaluation genuinely harder.
She's not saying peptides are dangerous. She's saying the science hasn't caught up to the hype, and that "fascinating science is not the same thing as proven therapies." That's a measured take, not a panic headline.
Does the science back this up?
Yes, and more than most influencers would admit. The natural-equals-safe assumption is a real cognitive bias with documented consequences in supplement research. The distinction she draws is pharmacologically sound.
Insulin is a peptide your body makes. Injecting exogenous insulin still causes hypoglycemia, weight changes, and requires careful dosing. GLP-1 is another endogenous peptide, and the clinical trial record for GLP-1 receptor agonists shows meaningful side effect profiles including nausea, pancreatitis risk, and thyroid concerns at pharmacological doses (Drucker, 2018, Cell Metabolism). The principle holds: endogenous origin does not cap pharmacological risk when you administer exogenous doses.
On the regulatory gap, she's also correct. The FDA's 2023 and 2024 actions on BPC-157 and other peptides placed several compounds on lists of drugs that cannot be compounded under 503A or 503B, precisely because their safety and efficacy data is insufficient for that pathway (FDA, 2024). The "research use only" label does not exempt a compound from drug regulations when it's being used in humans.
What did they get right or wrong?
She gets the pharmacology right, and the regulatory framing is accurate enough for a short-form video. The gray market characterization is fair. The point that "research purposes" labeling is legal cover rather than a scientific designation is accurate and underreported.
One place she's imprecise: she says these peptides "might be attained through research or compounding channels, currently the gray market." Compounding pharmacies operating under state pharmacy board licenses are not technically a gray market when they follow applicable law. The gray market label more accurately applies to peptides sold as research chemicals by unregulated vendors. That's a real distinction she collapses.
She also doesn't name specific peptides, which is both cautious and a bit frustrating. GHK-Cu, BPC-157, and TB-500 each have different evidence profiles, different regulatory statuses, and different risk considerations. Treating them as a category has limits. A viewer walks away with a general warning but no way to evaluate specific compounds they may already be using.
What should you actually know?
The endogenous-versus-exogenous distinction is one of the more important concepts in peptide research right now. Your body produces BPC-157 in gastric juice at low concentrations. Injecting milligram-range doses systemically is a different physiological event, and the rodent studies showing tissue repair effects (Sikiric et al., 2018, Current Pharmaceutical Design) have not been replicated in powered human clinical trials. That gap matters.
Long-term human safety data for most research peptides is essentially nonexistent. Cycling protocols shared online are not derived from clinical evidence. They are community conventions with no pharmacokinetic basis in peer-reviewed literature. If you are using peptides, this is the conversation to have with a licensed prescriber who can monitor labs, not a social media series, including this one.
- The FDA does not recognize most research peptides as approved therapies for human use.
- Compounding a peptide is only legal within a framework that requires a valid prescription and a legitimate patient-prescriber relationship.
- "Research use only" labeling does not make a substance legal to administer to yourself or others.